XENE

Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.

Xenon Pharmaceuticals (XENE) has drawn fresh attention after a sharp pullback, with the stock down about 38% over the past month and roughly 47% over the past 3 months.

Xenon Pharmaceuticals has seen a sharp reset in sentiment recently, with the share price falling 39.3% over the past month.

CEO Ian Mortimer and CFO Thomas Kelly purchased 45,000 shares of XENE in the open market.

Xenon Pharmaceuticals' (XENE) safety data has raised investor concerns about a potential Food and Dr

Xenon Pharmaceuticals (NASDAQ:XENE) said it has filed its first new drug application for azetukalner as a treatment for focal-onset seizures, while pausing portions of its late-stage psychiatry program to evaluate changes intended to improve tolerability.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) advanced its epilepsy program while encountering a new obstacle to expansion. On September 17, it submitted a New Drug Application to the U.S.

Analysts cut price targets and reduced their estimates for azetukalner's psychiatric commercial opportunity after Xenon Pharmaceuticals disclosed an enrollment pause in its Phase 3 depression trials -- XENE shares fell as much as 27.6%. NEW YORK, Sept.

Wall Street reacts as the drugmaker’s experimental medication hits a roadblock.